BNB Plus Faces Nasdaq Trading Suspension, Stock Plummets 99.99%

BNB Plus, which gained attention with its "digital asset finance" strategy linked to BNB, has been suspended from trading on Nasdaq. The business transition ended in failure in less than a year, causing the stock price to plummet by 99.99% in three years. According to Protoss on the 13th (local time), the company has entered the delisting process and has been pushed to the over-the-counter market. BNB Plus was previously the biotech company "Applied DNA Sciences." In the second half of last year, it declared a financial strategy involving large-scale purchases of BNB and raised $27 million. However, the stock price surged immediately after the public announcement but continued to decline thereafter. The company increased its BNB holdings, changed its ticker to BNBX, and rebranded as BNB Plus, but the stock price fell below $1. Ultimately, it failed to meet Nasdaq's listing maintenance requirements. The company holds approximately 18,700 BNB and $3.9 million in cash, but its market capitalization is only about $814,000, resulting in an 'mNAV' of 0.09 times. BNB Plus has stated that it will contest this action, but the trading suspension takes effect immediately. The market has already made a cold judgment.